{"id":937,"date":"2017-09-08T11:58:59","date_gmt":"2017-09-08T10:58:59","guid":{"rendered":"https:\/\/www.groupactionlawyers.co.uk\/blog\/?p=937"},"modified":"2017-09-08T11:58:59","modified_gmt":"2017-09-08T10:58:59","slug":"novo-nordisk-agrees-settlement-questionable-sales-tactics","status":"publish","type":"post","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics","title":{"rendered":"Novo Nordisk agrees to settlement for questionable sales tactics"},"content":{"rendered":"<p>Danish multinational pharmaceutical giant <em>Novo Nordisk<\/em> is one of the leading global manufacturers of medical drugs.<\/p>\n<p>They stand accused of using questionable tactics to drive up sales.<\/p>\n<p>Novo Nordisk reportedly took their marketing a step further by <strong>disguising salespeople as medical professionals and educators<\/strong>. The Novo Nordisk employees would apparently pretend to be experts in medicine and recommend the company&#8217;s own drugs like professors advertising their own textbooks to students. The drug maker is also accused of paying <em>kickbacks<\/em> to doctors and medical staff to encourage them to prescribe the company&#8217;s own medicines.<br \/>\n<!--more--><br \/>\nThis type of behaviour can have an adverse effect on competition as it can unfairly influence consumers&#8217; choice in the market. Along with recent allegations of collusion and price-hiking, these questionable marketing methods may adversely affect patient choice and the price paid for products in the market.<\/p>\n<h2>Behaviour revealed by whistle-blower<\/h2>\n<p>The alleged deceptive behaviour and bribery was revealed by a whistle-blower took the matter to court. The claims of illegal behaviour involved Novo Nordisk&#8217;s most popular drug, <em>Victoza<\/em>; an injectable medicine used by diabetics to help stimulate insulin production.<\/p>\n<h3>Are there health risks associated with the alleged behaviour?<\/h3>\n<p>All drugs come with their own risky side-effects. Sales people pretending to be medical experts could falsely inflate the benefits of a drug whilst downplaying the risks. Victoza&#8217;s most serious side-effect is reportedly the risk of thyroid tumours and cancer. Other serious side-effects include pancreatitis, hypoglycaemia, kidney failure and serious allergic reactions.<\/p>\n<p>The most common side-effects are:<\/p>\n<div class=\"well\">\n<ul class=\"blog-list\">\n<li>Headaches<\/li>\n<li>Nausea<\/li>\n<li>Diarrhoea<\/li>\n<li>Vomiting<\/li>\n<\/ul>\n<\/div>\n<p>The concerning questions posed, therefore, are whether anyone has been put at risk by the allegations made.<\/p>\n<h3>The importance of accurate medical information<\/h3>\n<p>When choosing drugs to prescribe, hospitals and doctors need to be presented with all the advantages and disadvantages of each drug, and prescribe according to a patient&#8217;s needs. With the Danish drug company&#8217;s alleged behaviour, there is a concern that patients could be prescribed Victoza when it would be more appropriate for them to take alternative medication.<\/p>\n<p>The common side-effects listed above may be a real concern for patients, but if countered with inflated benefits, a patient may take a drug when there could be a more suitable alternative. Victoza does not contain insulin itself and instead is supposed to stimulate parts of the body that create it. For some people, a drug that contains insulin may be more appropriate.<\/p>\n<h3>Company working with the authorities<\/h3>\n<p>Since Novo Nordisk&#8217;s alleged behaviour was revealed, the Danish drug company is reportedly working alongside U.S. authorities to bring the case to a conclusion. An email statement provided said:<\/p>\n<blockquote><p><strong><em>&#8220;&#8230;we&#8217;ve reached an agreement in principle to settle certain claims related to this investigation.&#8221;<\/em><\/strong><\/p><\/blockquote>\n<p>Signed by the company&#8217;s spokesman, Ken Inchausti, the settlement is not yet finalised.<\/p>\n<h3>Diabetes treatments: a lucrative venture<\/h3>\n<p>Diabetes treatments reportedly make up 80% of the company&#8217;s multi-billion dollar revenue, so it&#8217;s easy to see why they would want to keep pushing sales. In the past five years, drug sales have been on the rise, apparently increasing by 75%. Unfortunately, this growth may not be entirely credited to good marketing strategies and consumer need.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Danish multinational pharmaceutical giant Novo Nordisk is one of the leading global manufacturers of medical drugs. They stand accused of using questionable tactics to drive up sales. Novo Nordisk reportedly took their marketing a step further by disguising salespeople as medical professionals and educators. The Novo Nordisk employees would apparently pretend to be experts in &hellip; <a href=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Novo Nordisk agrees to settlement for questionable sales tactics<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":939,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1,5],"tags":[],"class_list":["post-937","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novo Nordisk Agrees To Settlement For Questionable Sales Tactics<\/title>\n<meta name=\"description\" content=\"The Danish multinational pharmaceutical giant accused of using questionable sales tactics for their injectable insulin product called Victoza.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Agrees To Settlement For Questionable Sales Tactics\" \/>\n<meta property=\"og:description\" content=\"The Danish multinational pharmaceutical giant accused of using questionable sales tactics for their injectable insulin product called Victoza.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics\" \/>\n<meta property=\"og:site_name\" content=\"Group Action Lawyers\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-08T10:58:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i2.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement-large.png?fit=1200%2C414&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement-large.png?fit=1200%2C414&ssl=1\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/3c954adf13d2913933b2069fbd6df781\"},\"headline\":\"Novo Nordisk agrees to settlement for questionable sales tactics\",\"datePublished\":\"2017-09-08T10:58:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics\"},\"wordCount\":537,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1\",\"articleSection\":[\"Latest\",\"Medical\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics\",\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics\",\"name\":\"Novo Nordisk Agrees To Settlement For Questionable Sales Tactics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1\",\"datePublished\":\"2017-09-08T10:58:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/3c954adf13d2913933b2069fbd6df781\"},\"description\":\"The Danish multinational pharmaceutical giant accused of using questionable sales tactics for their injectable insulin product called Victoza.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1\",\"width\":725,\"height\":250,\"caption\":\"novo nordisk settlement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/novo-nordisk-agrees-settlement-questionable-sales-tactics#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk agrees to settlement for questionable sales tactics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/\",\"name\":\"Group Action Lawyers\",\"description\":\"Latest Legal News, Articles &amp; Opinions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/3c954adf13d2913933b2069fbd6df781\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/author\\\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo Nordisk Agrees To Settlement For Questionable Sales Tactics","description":"The Danish multinational pharmaceutical giant accused of using questionable sales tactics for their injectable insulin product called Victoza.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics","og_locale":"en_GB","og_type":"article","og_title":"Novo Nordisk Agrees To Settlement For Questionable Sales Tactics","og_description":"The Danish multinational pharmaceutical giant accused of using questionable sales tactics for their injectable insulin product called Victoza.","og_url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics","og_site_name":"Group Action Lawyers","article_published_time":"2017-09-08T10:58:59+00:00","og_image":[{"width":1200,"height":414,"url":"https:\/\/i2.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement-large.png?fit=1200%2C414&ssl=1","type":"image\/png"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement-large.png?fit=1200%2C414&ssl=1","twitter_misc":{"Written by":"Admin","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#article","isPartOf":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics"},"author":{"name":"Admin","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/3c954adf13d2913933b2069fbd6df781"},"headline":"Novo Nordisk agrees to settlement for questionable sales tactics","datePublished":"2017-09-08T10:58:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics"},"wordCount":537,"commentCount":0,"image":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1","articleSection":["Latest","Medical"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics","url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics","name":"Novo Nordisk Agrees To Settlement For Questionable Sales Tactics","isPartOf":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage"},"image":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1","datePublished":"2017-09-08T10:58:59+00:00","author":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/3c954adf13d2913933b2069fbd6df781"},"description":"The Danish multinational pharmaceutical giant accused of using questionable sales tactics for their injectable insulin product called Victoza.","breadcrumb":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#primaryimage","url":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1","width":725,"height":250,"caption":"novo nordisk settlement"},{"@type":"BreadcrumbList","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novo-nordisk-agrees-settlement-questionable-sales-tactics#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.groupactionlawyers.co.uk\/blog"},{"@type":"ListItem","position":2,"name":"Novo Nordisk agrees to settlement for questionable sales tactics"}]},{"@type":"WebSite","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#website","url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/","name":"Group Action Lawyers","description":"Latest Legal News, Articles &amp; Opinions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.groupactionlawyers.co.uk\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/3c954adf13d2913933b2069fbd6df781","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g","caption":"Admin"},"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/author\/admin"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/novo-nordisk-settlement.png?fit=725%2C250&ssl=1","jetpack-related-posts":[{"id":1064,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/novopen-insulin-pens-recalled-over-hyperglycaemia-risk","url_meta":{"origin":937,"position":0},"title":"NovoPen insulin pens recalled over risk of hyperglycaemia","author":"Admin","date":"6th November 2017","format":false,"excerpt":"Certain batches of insulin pens manufactured by Novo Nordisk have been recalled as the cartridge holders may not be strong enough to withstand some household cleaners. The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a medical device alert to notify hospitals and users to return affected batches to\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":942,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/drug-manufacturers-distributors-suspected-colluding-inflate-profits","url_meta":{"origin":937,"position":1},"title":"Major drug manufacturers and distributors suspected of colluding to inflate profits at consumers&#8217; expense","author":"Admin","date":"11th September 2017","format":false,"excerpt":"Several drug manufacturers, suppliers and pharmacy benefit managers have reportedly been caught colluding to fix prices for insulin. In what's believed to be efforts to allegedly inflate profits, companies reportedly worked together to set consistently high prices for the drugs. This way, no matter where consumers purchased their insulin from,\u2026","rel":"","context":"In &quot;Latest&quot;","block_context":{"text":"Latest","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/latest"},"img":{"alt_text":"drugs","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":962,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/lawsuit-filed-against-epipen-manufacturer-alleged-price-gouging","url_meta":{"origin":937,"position":2},"title":"Lawsuit filed against EpiPen manufacturers for alleged &#8220;price gouging&#8221;","author":"Admin","date":"20th September 2017","format":false,"excerpt":"A lawsuit has been filed against a medical manufacturer who are alleged to have charged higher prices for its asthma medication. High charges for asthma medication is a hot topic here in the U.K., with many believing it's not something people should have to pay for. The EpiPen - the\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3238,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/securing-mass-compensation-for-dangerous-drug-victims-through-group-actions","url_meta":{"origin":937,"position":3},"title":"Securing Mass Compensation for Dangerous Drug Victims Through Group Actions","author":"Author","date":"13th January 2026","format":false,"excerpt":"Pharmaceutical negligence can devastate lives, but victims no longer need to fight alone. The Group Action Lawyers specialises in uniting affected individuals to pursue mass compensation for dangerous drug cases via powerful group actions. This article explains how these claims work, who qualifies, and why joining forces can maximise your\u2026","rel":"","context":"In &quot;Group Actions&quot;","block_context":{"text":"Group Actions","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/group-actions"},"img":{"alt_text":"mass compensation for dangerous drug","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/A-USED-DBL-DLL-Group-action-6-Copy-min.jpg?fit=850%2C649&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/A-USED-DBL-DLL-Group-action-6-Copy-min.jpg?fit=850%2C649&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/A-USED-DBL-DLL-Group-action-6-Copy-min.jpg?fit=850%2C649&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/A-USED-DBL-DLL-Group-action-6-Copy-min.jpg?fit=850%2C649&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":1761,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/xarelto-compensation-settlements","url_meta":{"origin":937,"position":4},"title":"Xarelto compensation settlements","author":"Author","date":"16th April 2019","format":false,"excerpt":"Big news! Xarelto compensation settlements are taking place, with almost \u00a3600m in damages set to be paid out by Bayer AG and Johnson & Johnson. The settlements are for around 25,000 lawsuits in the U.S., where Bayer and J&J have reportedly agreed to settle the litigation for $775m. The Group\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":879,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/medtronic-infuse-lawsuits-coming-close","url_meta":{"origin":937,"position":5},"title":"Medtronic: &#8220;Infuse lawsuits coming to a close&#8221;","author":"Author","date":"11th August 2017","format":false,"excerpt":"Medical device company, Medtronic, has recently suffered a lengthy legal headache when the company faced allegations of defrauding shareholders by reportedly covering up negative side-effects of its Infuse bone growth product for 10 years. Infuse is a genetically engineered protein that causes bones to fuse for use during lower spinal\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"medtronic infuse lawsuits","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/medtronic-infuse-lawsuits-min.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/medtronic-infuse-lawsuits-min.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/medtronic-infuse-lawsuits-min.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/medtronic-infuse-lawsuits-min.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=937"}],"version-history":[{"count":2,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/937\/revisions"}],"predecessor-version":[{"id":941,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/937\/revisions\/941"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media\/939"}],"wp:attachment":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}